HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Porphyria Cutanea Tarda

An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form.
Networked: 993 relevant articles (42 outcomes, 48 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Erythropoietic Protoporphyria
2. Infections
3. Systemic Lupus Erythematosus (Libman-Sacks Disease)
4. Hemochromatosis (Bronze Diabetes)
5. Acute Intermittent Porphyria (Porphyria, Acute)

Experts

1. Frank, Jorge: 7 articles (03/2022 - 06/2004)
2. Anderson, Karl E: 7 articles (11/2019 - 02/2002)
3. Desnick, Robert J: 7 articles (11/2019 - 03/2011)
4. Phillips, J D: 7 articles (07/2009 - 11/2000)
5. To-Figueras, Jordi: 6 articles (01/2020 - 02/2002)
6. Phillips, John D: 6 articles (11/2019 - 11/2005)
7. Stölzel, U: 6 articles (12/2018 - 11/2000)
8. Bonkovsky, Herbert L: 6 articles (01/2013 - 04/2002)
9. Kushner, J P: 6 articles (07/2009 - 11/2000)
10. Poblete-Gutiérrez, Pamela: 5 articles (03/2022 - 06/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Porphyria Cutanea Tarda:
1. Chloroquine (Aralen)FDA LinkGeneric
2. Hydroxychloroquine (Plaquenil)FDA LinkGeneric
3. PorphyrinsIBA
4. Cimetidine (Biomet)FDA LinkGeneric
5. IronIBA
6. Uroporphyrinogen Decarboxylase (Uroporphyrinogen III Decarboxylase)IBA
7. Antimalarials (Antimalarial Agents)IBA
8. Antiviral Agents (Antivirals)IBA
9. Anastrozole (Arimidex)FDA LinkGeneric
10. Deferoxamine (Desferal)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Renal Dialysis (Hemodialysis)
3. Radiotherapy
4. Surgical Amputation (Amputations)
5. Blood Transfusion (Blood Transfusions)